:max_bytes(150000):strip_icc()/GettyImages-2229305720-fcfb57124467458e9d09172ea962a5ce.jpg)
ETHZilla, the recently rebranded crypto treasury firm focused on Ether, announced an immediate $250 million stock repurchase plan, leading to a 9% surge in its shares. The company, which recently pivoted from therapeutic drugs, now holds 102,237 Ether valued at approximately $489 million, acquired at an average price of $3,948.72, alongside $215 million in USD stablecoins. This aggressive buyback underscores management's commitment to maximizing shareholder value by leveraging its significant Ether treasury and new strategic direction.
ETHZilla (ETHZ), formerly 180 Life Sciences, has signaled strong confidence in its new strategic direction with the announcement of an immediate $250 million stock repurchase program, which catalyzed a 9% rise in its share price. This move follows the company's recent and complete pivot from therapeutic drugs to becoming an accumulation vehicle for Ether (ETH). The firm's balance sheet is now dominated by digital assets, comprising 102,237 ETH with a market value of approximately $489 million and an additional $215 million in USD stablecoins. The buyback represents a significant capital return, leveraging a treasury whose ETH holdings were acquired at an average price of $3,948.72, below the current market price of roughly $4,665. The executive chair's statement framing the buyback as an "aggressive" program to maximize shareholder value suggests management believes the stock is trading at a discount to its underlying net asset value, which is now almost entirely tied to the crypto market.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment